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http://dx.doi.org/10.1016/j.ccr.2013.11.003SUMMARYDiffuse large B cell lymphoma (DLBCL) is a biologically heterogeneous and clinically aggressive disease.
Here, we explore the role of bromodomain and extra-terminal domain (BET) proteins in DLBCL, using integra-
tive chemical genetics and functional epigenomics. We observe highly asymmetric loading of bromodomain
4 (BRD4) at enhancers, with approximately 33% of all BRD4 localizing to enhancers at 1.6% of occupied
genes. These super-enhancers prove particularly sensitive to bromodomain inhibition, explaining the selec-
tive effect of BET inhibitors on oncogenic and lineage-specific transcriptional circuits. Functional study of
genes marked by super-enhancers identifies DLBCLs dependent on OCA-B and suggests a strategy for
discovering unrecognized cancer dependencies. Translational studies performed on a comprehensive panel
of DLBCLs establish a therapeutic rationale for evaluating BET inhibitors in this disease.INTRODUCTION
Diffuse large B cell lymphoma (DLBCL) is the most common
form of non-Hodgkin’s lymphoma in adults. The majority of
DLBCLs arise from antigen-exposed B cells during the germinal
center (GC) reaction, a process that optimizes the affinity of
antibodies for antigens (Klein and Dalla-Favera, 2008). Despite
significant advances in the biological understanding of DLBCL
pathogenesis, current treatment regimens include empiric
combination immuno/chemotherapy at induction and relapse.Significance
Although oncogenic transcription factors underlie the pathoph
lymphoma (DLBCL), studies of transcriptional coactivator prote
we demonstrate the efficacy of bromodomain and extra-termin
tion of BET bromodomains in supporting the transcriptional gr
vation of E2F and MYC target genes. We define an asymmetr
nearby oncogenic and master regulatory genes and expand th
samples. This finding likely explains the specific transcription
of master transcription factors that control B cell fate and ger
CaMechanistic insights guiding the development of targeted thera-
peutic agents are urgently needed, as relapsed and refractory
disease comprise significant unmet medical needs (Gisselbrecht
et al., 2010).
DLBCL exhibits significant biological heterogeneity. Gene
expression profiling has allowed functional classification of
tumors into distinct subgroups. Presently, DLBCL is described
using two transcriptional classifications, commonly referred to
as the cell of origin (COO) and the consensus clustering classifi-
cation (CCC). The COO classification relates subsets of DLBCLysiology and biological heterogeneity of diffuse large B cell
ins are limited in this disease. In this chemical genetic study,
al domain (BET) inhibition and characterize the broad func-
owth program in all subclasses of DLBCL, including coacti-
y in the localization of bromodomain 4 to enhancer regions
e finding to a representative panel of cell lines and primary
al effect of BET inhibition, which modulates the expression
minal center formation.
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tumors to either a germinal center-B (GCB) or activated B cell
(ABC) subtype (Lenz and Staudt, 2010). The CCC classification
defines three groups of DLBCLs on the basis of transcriptional
heterogeneity solely within tumors. Here, DLBCL subtypes rely
on B cell receptor (BCR) survival signals and glycolysis (BCR)
or BCR-independent fuel utilization and oxidative phosphoryla-
tion (OxPhos), or they exhibit an increased inflammatory and
immune cell infiltrate (host response) (Caro et al., 2012; Chen
et al., 2013; Monti et al., 2005). Both classifications provide
insights into disease pathogenesis and suggest potential tumor
cell dependencies and rational therapeutic targets.
Several genome sequencing studies of DLBCL defining the
mutational landscape have revealed substantial genetic hetero-
geneity (Lohr et al., 2012; Morin et al., 2011; Pasqualucci et al.,
2011; Zhang et al., 2013). In contrast to Burkitt lymphoma (BL),
another germinal center-derived tumor characterized by a
hallmark t(8;14) translocation of MYC into the immunoglobulin
heavy- or light-chain enhancer region, DLBCLs have high
genotypic diversity. These tumors exhibit multiple low-frequency
copy number alterations (CNAs), additional chromosomal
translocations, and over 50 recurrent somatic mutations (Lohr
et al., 2012; Monti et al., 2012; Morin et al., 2011; Pasqualucci
et al., 2011). In DLBCL, the underlying biological and genetic
heterogeneity are associated with highly variable clinical out-
comes, ranging from long-term overall survival (‘‘cure’’) to rapidly
progressive disease (Monti et al., 2012).
Mechanistically, the transcriptional heterogeneity of DLBCL is
conferred, in part, by pathologic activation or inactivation of
lineage-specific and growth-associated master regulatory
transcription factors (TFs), including NF-kB (Lenz and Staudt,
2010), BCL6 (Basso and Dalla-Favera, 2012), MYC (Slack and
Gascoyne, 2011), and p53 (Monti et al., 2012), and also through
upstream pathway deregulation. Recently, we demonstrated
that multiple, low-frequency CNAs converge functionally to
deregulate p53 and cell cycle, resulting in increased proliferation
and enhanced signaling from the master regulatory transcription
factor E2F1 (Monti et al., 2012). In this study, deregulated cell
cycle and increased expression of E2F1 target genes were asso-
ciated with inferior outcome (Monti et al., 2012). In recent
studies, a newly defined subset of ‘‘double-hit’’ DLBCLs that
overexpress MYC in association with BCL2 also have an unfa-
vorable outcome (Hu et al., 2013; Johnson et al., 2012).
Together, these findings underscore the centrality of master
regulatory TFs in DLBCL.
TFs control cancer cell state by binding proximal (promoter)
and distal (enhancer) regulatory elements (Lee and Young,
2013). The subsequent recruitment of multiprotein complexes
leads to local remodeling of chromatin, which establishes
mitotic memory, and transmission of transcriptional signals to
RNA polymerase II (RNA Pol II) poised at genes associated
with growth and survival (Fuda et al., 2009; Schreiber and
Bernstein, 2002). Chromatin associated with TF binding sites is
markedly enriched in histone proteins posttranslationally
modified by lysine side-chain acetylation (Marushige, 1976).
This mark biophysically facilitates opening of chromatin and
recruits an emerging class of coactivators that recognize
ε-acetyl lysine through a specialized recognition motif or bromo-
domain (Owen et al., 2000).778 Cancer Cell 24, 777–790, December 9, 2013 ª2013 Elsevier Inc.Among the 46 known bromodomain-containing proteins (Fili-
ppakopoulos et al., 2012), the subfamily of bromodomain and ex-
tra-terminal domain (BET) coactivators (BRD2, BRD3, andBRD4)
are particularly appealing targets in DLBCL. Structurally, BET
proteins possess twin amino-terminal bromodomains that facili-
tate binding to hyperacetylated promoter/enhancer regions (Fili-
ppakopoulos et al., 2012; Zhang et al., 2012), as well as a distal
carboxy-terminal binding site for the positive transcription elon-
gation factor (P-TEFb; Bisgrove et al., 2007). In cancer, BET bro-
modomains promote M to G1 cell cycle progression (Yang et al.,
2008) and contribute to mitotic memory (Dey et al., 2003; Zhao
et al., 2011). Collaborative research from our group and others
has recently identified a role for BET bromodomains in support-
ing the transcription of known DLBCL oncogenes (MYC and
BCL2) in studies of acute leukemia, multiple myeloma, and BL
(Dawson et al., 2011; Delmore et al., 2011; Mertz et al., 2011;
Ott et al., 2012; Zuber et al., 2011). Interestingly, overexpression
of BRD2 from an engineered immunoglobulin heavy-chain
promoter-enhancer construct caused an aggressive B cell
neoplasm resembling DLBCL in mice (Greenwald et al., 2004).
Together, the findings establish a compelling hypothesis that
BET bromodomains serve as chromatin-associated modulators
of major gene regulatory pathways in DLBCL.
In an effort to study the role of BET bromodomains in cancer,
we recently developed specific inhibitors of BET transcriptional
coactivator proteins (Filippakopoulos et al., 2010), including
a prototypical triazolo-diazepine inhibitor of the acetyl-lysine
binding site, JQ1. Here, we explore the role of BET bromodo-
mains in oncogenic transcription by master regulatory TFs and
assess BRD4 as a therapeutic target in DLBCL.
RESULTS
BET Bromodomain Inhibition Exerts Pan-Subtype
Growth Arrest in DLBCL and in BL
To assess the role of BET bromodomains as cancer cell depen-
dencies in DLBCL, we first studied the effects of four structurally
dissimilar BET bromodomain inhibitors on a comprehensive
panel of 34 human lymphoma cell lines (21 DLBCL, capturing
all transcriptionally defined subtypes, 6 BL, and 7 Hodgkin’s
lymphoma [HL]; Table S1 available online) in comparative high-
throughput format. In addition to the prototypical BET inhibitor
JQ1 (JQ1S) (Filippakopoulos et al., 2010), we resynthesized,
characterized, and tested an analogous thienodiazepine from
Mitsubishi-Tanabe Pharmaceutical (Y803, OTX015; Oncoethix),
which was developed for inflammatory bowel disease (Fig-
ure S1A; Miyoshi et al., 2009), a benzodiazepine inhibitor (iBET;
Nicodeme et al., 2010), and a dimethylisoxazole inhibitor
(iBET-151) fromGlaxoSmithKline (Dawson et al., 2011). Analyses
of cellular proliferation at 72 hr revealed a potent class effect of
BET bromodomain inhibitors on the DLBCL and BL cell lines
irrespective of subtype and the lack of effect of an inactive
enantiomer, JQ1R (Figure 1A). The HL cell lines were compara-
tively less sensitive to BET inhibition and one HL line, L428,
was resistant to all four compounds.
TheeffectsofBET inhibitionongrowthover time, cell cyclepro-
gression, and apoptosis were then studied in a representative
panel of nine DLBCL cell lines, using the L428 HL line as a nega-
tive control (Figures 1B, 1C, S1B, and S1C). BET inhibition with
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in all tested DLBCL cell lines (Figure 1B). In three representative
DLBCL cell lines, genetic depletion of BRD2 or BRD4 similarly
decreased DLBCL proliferation, consistent with an on-target ef-
fect of JQ1 (Figures S1D–S1G).We observed a profound Sphase
andG2peak reduction following JQ1 treatment, consistentwith a
G1 cell cycle arrest (Figures 1C and S1B). BET inhibition (500 nM)
did not induce apoptosis in most cell lines studied, evidenced by
low AnnexinV/7AAD staining (Figure S1C) and absence of a sub-
G1 peak (Figure 1C). Neither enantiomeric (JQ1R) nor vehicle
(DMSO) controls affectedDLBCLproliferation or survival (Figures
1C, S1B, and S1C). Treatment with 500 nM JQ1 was similarly
cytostatic in BL cell lines (Figure S1C). The L428 HL cell line
was resistant to BET inhibition in all tested assays.
Efficacy of BET Inhibition in DLBCL Xenograft Models
We next explored the therapeutic potential of BET inhibition in
two independent DLBCL xenotransplantation models (Figures
1D–1G and S1H–S1K). First, the human DLBCL cell line Ly1
was engineered to ectopically express firefly luciferase and
mCherry, allowing surrogate measurement of tumor growth
in vivo. Nonobese diabetic severe combined immunodeficiency
IL2Rgnull (NSG) mice xenotransplanted with Ly1-Luc-mCherry
cells had a statistically significant reduction in tumor burden
when treated with JQ1 (30 mg twice daily by intraperitoneal [IP]
injection; Figure 1D). A representative cohort of animals was
sacrificed on day 13 of treatment for full hematological analysis.
JQ1-treated animals had significantly decreased lymphoma
infiltration of the bone marrow (BM) as measured by flow cyto-
metric assessment of mCherry+ cells (Figure 1E). Morphological
and immunohistochemical analyses revealed that the highly
proliferative (Ki67+) human CD20+ lymphoma cell infiltrate (Fig-
ure 1F, upper panel) was markedly reduced in animals treated
with the BET bromodomain inhibitor (Figure 1F, lower panel). In
the remainder of the Ly1 xenograft cohort, the JQ1-treated
mice had a significant median overall survival advantage of
9 days (p = 0.003; Figure 1G).
To confirm the pharmacodynamic findings, a second xeno-
transplantation model was established using the Toledo DLBCL
cell line. NSG mice with established tumors had delayed tumor
progressionwhen treatedwith JQ1 (Figure S1H). Full hematolog-
ical analysis revealed that JQ1-treated animals had lower spleen
weights (Figure S1I) and decreased lymphomatous infiltration of
bone marrow and spleen (Figure S1J). Morphological and immu-
nohistochemical analysis of the BM revealed significantly
reduced the infiltration of CD20+/Ki67+ human lymphoma cells
following BET inhibition (Figure S1K).
BET Inhibition Downregulates Oncogenic
Transcriptional Pathways
To gain insights into the transcriptional pathways regulated
by BET bromodomain coactivator proteins, we performed
kinetic transcriptional profiling of vehicle- and JQ1-treated
DLBCL cell lines. Five human DLBCL cell lines that captured
the recognized transcriptional heterogeneity (Ly1, BCR/GCB;
DHL6, BCR/GCB; Ly4, OxPhos/unclassified; Toledo, OxPhos/
unclassified; and HBL1, BCR/ABC) were treated with JQ1
(500 nM) or vehicle control for 0, 2, 6, 12, 24, and 48 hr. At
each time point, differential analysis was performed betweenCathe vehicle- and JQ1-treated samples (24 hr comparison, fold
change (FC) > 1.3, false discovery rate (FDR) < 0.01; Figure S2A).
Consistent with prior studies of BET bromodomain function and
inhibition, HEXIM1 was markedly upregulated by JQ1 in all
DLBCL cell lines (Figure S2B; Bartholomeeusen et al., 2012;
Puissant et al., 2013).
The most differentially expressed genes were assessed for
pathway enrichment using a comprehensive pathway compen-
dium (C2, CP; MSigDB 3.0), and each time point was ranked
by FDR and visualized as a color-coded matrix (Figure 2A; full
list in Table S2). We observed the early downregulation of
MYD88/toll-like receptor (TLR) pathway components following
JQ1 treatment, including TLR10 and MYD88 (Figures 2A–2C
and S2C). These data are consistent with previous studies in
which the anti-inflammatory effect of BET inhibition in normal B
cells was attributed to TLR pathway downregulation (Nicodeme
et al., 2010). In the JQ1-treated DLBCL cell lines, we also
observed downregulation of multiple components of the BCR
signaling pathway, E2F transcriptional targets, and additional
cell cycle transition gene sets (Figures 2A and S2D). Similar re-
sults were obtained when GCB and ABC DLBCL cell lines
were analyzed separately (Figures S2E and S2F).
BET Inhibition Modulates MYC and E2F Target Gene
Transcription
Cell state transitions are influenced by the function of specific
regulatory TFs. To identify candidate TFs associated with
BET bromodomain coactivators, we assessed the effects of
JQ1 on sets of genes with common TF binding motifs (C3;
MSigDB 3.0). The differentially expressed genes in vehicle-
versus JQ1-treated DLBCL cell lines were tested for enrichment
of candidate TF targets at 2–48 hr. Results at each time point
were ranked by FDR and visualized as a color-codedmatrix (Fig-
ure 2D; Table S2).
It is of interest that gene sets withMYC and E2F binding motifs
were significantly downregulated following JQ1 treatment
(Figure 2D). To further evaluate the effects of BET bromodomain
inhibition on MYC and E2F transcriptional programs, we used
multiple functionally validated MYC and E2F target gene sets
to perform directed pathway analyses. Following JQ1 treatment,
there was highly significant early downregulation of well-defined
and functionally validated MYC and E2F target gene sets
(Figures 2E, 2F, S2G, and S2H). In complementary studies, we
performed gene set enrichment analyses (GSEA) of multiple
independent MYC and E2F target gene sets in vehicle- versus
JQ1-treated samples and found that MYC and E2F targets
were significantly less abundant in JQ1-treated cells (Figures
2F, S2I, and S2J).
BET bromodomain proteins may function as coactivators of
the MYC and E2F proteins and/or as direct modulators of MYC
and E2F expression. To distinguish between these possibilities,
we assessed the transcript abundance and protein levels of
MYC and E2F in vehicle- and JQ1-treated DLBCLs. BET bromo-
domain inhibition resulted in an apparent decrease in MYC
transcripts and protein in each of the DLBCL cell lines (Figures
2G, S2K, and S2L), suggesting that BET bromodomains directly
modulate MYC transcription. The consequences of MYC
downregulation following BET inhibition have been character-
ized by our group and others in hematologic malignanciesncer Cell 24, 777–790, December 9, 2013 ª2013 Elsevier Inc. 779
Figure 1. In Vitro Analyses of BET Bromodomain Inhibition in Various B Cell Lymphomas
(A) Hierarchical clustering of mean EC50s of the four BET inhibitors (72 hr treatment) in the indicated panel of B cell lymphoma cell lines. EC50 values in a
colorimetric scale: very sensitive (%1 mM) in red, sensitive (=1 mM) in white, to resistant (R10 mM) in black. Corresponding structures are shown.
(B) Proliferation of the indicated DLBCL and HL cell lines treated with vehicle or 250-1000 nM JQ1 for 1-4 days.
(C) Cell cycle analysis following 72 hr treatment with JQ1 (500 nM) or inactive enantiomer JQ1R (500 nM). Error bars represent the SD of triplicates.
(D) Bioluminescence of JQ1 (30 mg/kg IP twice daily) or vehicle-treated NSG mice xenotransplanted with luciferized mCherry+ Ly1 cells. Asterisks indicate
p < 0.05 using a one-sided t test. Error bars represent SEM.
(E) Lymphoma infiltration of BM in a representative set of animals was assessed by flow cytometric analysis of mCherry+ cells and visualized as scatter plots
(median, line; whiskers, SEM). The p values were obtained with a one-sided Mann-Whitney U test.
(legend continued on next page)
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Zuber et al., 2011). Notably, ectopic expression of MYC in
DLBCL cell lines failed to rescue the antiproliferative effects of
JQ1 (Figures S2M–S2O), also consistent with a model in which
BET bromodomains function as coactivators of MYC target
gene transcription. In contrast to effects on MYC expression,
in four of five cell lines, JQ1 treatment did not measurably alter
E2F1 transcript or protein abundance over 24 hr (Figures 2G,
S2P, and S2Q). These data suggest that BET bromodomains
may function at regulatory elements at E2F1 target genes, rather
than by influencing the abundance of E2F1 itself.
BET Bromodomains as Promoter-Bound Coactivators of
E2F1-Dependent Transcription
To explore the role of BETs as coactivators of oncogenic E2F1
transcriptional signaling, we performed chromatin immunopre-
cipitation with massively parallel sequencing (ChIP-seq), using
a chemical genetic approach. We selected Ly1 cells for mecha-
nistic consideration owing to the robust downregulation of E2F
target genes in the transcriptional profiling (Figure S3A) and the
lack of effect of JQ1 on E2F1 protein expression (Figure 2G).
Changes in BET localization, chromatin structure, and RNA
polymerase function were studied in Ly1 cells treated with JQ1
(500 nM) or vehicle control.
First, we established a chromatin landscape for Ly1 using
H3K4me3 to identify promoters, H3K27ac to reveal enhancers,
and H3K27me3 to define repressive regions of the genome.
Then, we assessed the genome-wide localization of E2F1 and
the representative BET protein, BRD4, also by ChIP-seq using
the respective antibodies. Rank ordering of all transcriptionally
active promoters based on H3K4me3 enrichment and RNA Pol
II occupancy identifies pervasive binding of BRD4 and E2F1 to
active promoter elements (Figure 3A). Analysis of enrichment
data as a metagene of all active promoters centered on the tran-
scription start site reveals spatial colocalization of E2F1 and
BRD4 at all transcriptionally active promoters (Figure 3B).
ChIP-seq for E2F1 allowed the annotation of an E2F1 target
gene set, based on the top promoter-bound genes in Ly1 cells
(Table S3). Using a gene set of the top 100 ChIP-seq-defined
E2F1 targets (Table S3), we performed GSEA in Ly1 and addi-
tional DLBCL cell lines DHL6, Ly4, Toledo, and HBL1. JQ1 treat-
ment significantly decreased the transcript abundance of our
functionally defined E2F1 targets at 24 hr and 48 hr in all cell lines
studied (Figures 3C and S3A). The E2F1 dependency of these
DLBCL cell lines as previously reported (Monti et al., 2012) was
validated herein by genetic depletion in three representative
cell lines (Figures 3D, 3E, S3B, and S3C). Together, these data
mechanistically establish BET bromodomains as E2F1 coactiva-
tors in DLBCL.
Disproportionate Binding of BRD4 to Overloaded
Enhancers
At the time this research was initiated, studies of BET bromodo-
mains mainly focused on effects at promoter regions of the(F) Immunohistochemical analysis of lymphoma (Ly1) BM infiltration in JQ1- and v
Ki67 immunostaining. Scale bar represents 100 mm.
(G) Kaplan-Meier plot of the remainder of the Ly1 cohort (n = 21) treated with either
See also Figure S1 and Table S1.
Cagenome. Our research in multiple myeloma identified a role for
BRD4 in enforcing MYC transcription from the translocated
immunoglobulin H (IgH) enhancer locus (Delmore et al., 2011),
where massive accumulation of BRD4 was identified by ChIP
(approximately 200-fold enrichment). As oncogenic TFs may
signal to RNA Pol II through distal enhancer elements, we sought
to characterize the genome-wide localization of BRD4 to en-
hancers in DLBCL.
Rank ordering of enhancer regions by H3K27ac enrichment
reveals that BRD4 binds to the vast majority of active enhancers
in the Ly1 DLBCL genome (Figure 4A, blue and red tracks). Given
the established role of BCL6 in the pathogenesis of DLBCL, we
also documented genome-wide colocalization of BRD4 and
BCL6 at H3K27ac-defined enhancers (Figure 4A, orange tracks).
A metagene for active enhancers illustrates focal, superimpos-
able enrichment for BRD4 with H3K27ac (Figure 4B). The corre-
lation between BRD4 occupancy and H3K27 acetylation is
extremely strong genome wide, with 79.1% of H3K27ac regions
containing BRD4 and 92.2% of all chromatin-bound BRD4
occurring in regions marked by H3K27ac (Figure 4C). Genome-
wide binding data for BRD4 reveal that BRD4 is most commonly
associated with enhancer regions, defined by the presence of
H3K27ac and absence of H3K4me3 (Figure 4D).
As predicted, BRD4 load is asymmetrically distributed
throughout the genome at enhancer sites. Completely unex-
pected is the magnitude by which BRD4 load varies among
active enhancer regions (Figure 4E). Only a small subset of
BRD-loaded enhancers, 285/18,330 (1.6%), account for 32%
of all of the BRD4 enhancer binding in the cell (Figure 4E; Table
S4). The BRD4-loaded enhancers in the Ly1 DLBCL cell line are
considerably larger than typical enhancer elements, resembling
the super-enhancers (SEs) we recently described with Richard
Young (Love´n et al., 2013).
Notably, the top two gene loci with BRD4-loaded enhancers,
POU2AF1 (which encodes theOCA-B transcriptional coactivator
protein) and BCL6, and additional genes with disproportionally
BRD4-loaded enhancers such as PAX5 and IRF8 (Figure 4E),
are essential for B cell fate determination and germinal center
formation (Basso and Dalla-Favera, 2012; Klein and Dalla-Fa-
vera, 2008; Teitell, 2003; Wang et al., 2008). In fact, mice with
genetic ablation of POU2AF1, BCL6, PAX5, or IRF8 lack the
ability to form germinal centers, the physiological structures
from which most DLBCLs arise (Cobaleda et al., 2007; Nutt
et al., 2011; Teitell, 2003;Wang et al., 2008; Ye et al., 1997). Addi-
tionally, BRD4-superloaded enhancers are found adjacent to
known oncogenes relevant to DLBCL biology, such as CD79B
and MYC (Figures S4A and S4B).
These data indicate that BRD4 is predominantly an enhancer-
associated factor, which distributes throughout DLBCL euchro-
matin in a highly asymmetric manner, adjacent to known
oncogenes and lineage-specific transcription factors (Figure 4E).
BET bromodomain inhibition selectively decreased the tran-
script abundance of the 285 genes with the most BRD4-loaded
SEs, in contrast to the 285 genes with the least BRD4-loadedehicle-treated mice: hematoxylin and eosin (H&E), anti-human CD20, and anti-
vehicle or JQ1 30mg/kg twice daily. The p value was obtained by log rank test.
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Figure 2. Transcriptional Response to BET Inhibition in Representative DLBCL Cell Lines
(A) Hyperenrichment analysis of differentially expressed genes in all five lines (FDR < 0.01; FC > 1.3) following 24 hr of treatment with 500 nM JQ1 or vehicle was
performed using a pathway compendium (MSigDB, C2.CP). Results at each time point were ranked by FDR and visualized as a color-coded matrix. Upregulated
pathways are in red, and downregulated pathways are in blue. Intensity of color correlates with FDR significance level. Highlighted pathways include:
TLR/MYD88, blue; BCR signaling, green; and cell cycle/E2F, cyan.
(legend continued on next page)
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Figure 3. Colocalization and Function of
BRD4 and E2F1 at Active Promoters
(A) Heatmap of ChIP-seq reads for RNA Pol II
(transcriptionally active; black), H3K4me3 (green),
BRD4 (red), and E2F1 (blue) rank ordered from
high to low RNA Pol II occupancy centered on a
±5 kb window around the TSS of all transcrip-
tionally active promoters. Color density reflects
enrichment; white indicates no enrichment.
(B) Metagenes created from normalized genome-
wide average of reads for designated factors
centered on a ±2 kb window around the TSS.
(C) GSEA plots of a ChIP-seq-defined E2F1 target
gene set in the five DLBCL cell lines treated with
vehicle versus JQ1 for 24 and 48 hr.
(D) Assessment of proliferation in Ly1 cell line
following genetic depletion of E2F1 with two in-
dependent hairpins and a control hairpin (ev). Error
bars represent SD, and asterisks show p < 0.01 by
a two-sided Student’s t test.
(E) Immunoblot of E2F1 of cells in (D) to demon-
strate knockdown efficiency.
See also Figure S3 and Table S3.
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H3K27ac as surrogate enhancer mark (Figure S4C). Taken
together, these data suggest that BRD4 loading of select DLBCL
enhancers underlies the pathway-specific transcriptional conse-
quences of BET inhibition.
JQ1 Targets the POU2AF1 SE and Decreases OCA-B
Expression and Activity
The POU2AF1 locus emerged as the most BRD4-overloaded
enhancer in the Ly1 DLBCL cell line (Figure 4E), prompting
further analysis of the effect of BET inhibition on OCA-B expres-
sion and function. OCA-B is a gene regulatory factor that
interacts with the OCT1 and OCT2 TFs at octamer motifs and
regulates B cell development, maturation, and GC formation
(Teitell, 2003). Although OCA-B is expressed throughout B cell
development, it is most abundant in normal GCB cells and GC-
derived tumors, including DLBCL (Greiner et al., 2000).(B) Mean transcript abundance of TLR10 (left) and MYD88 (right) in all five lines. Error bars represent SEM.
(C) Heatmap of TLR pathway components in vehicle- or JQ1-treated DLBCLs (all five lines; 24 hr).
(D) The most differentially expressed genes (FDR < 0.01; FC > 1.3) were analyzed for common TF binding s
compendium. Results at each time point were ranked using a color-coded matrix as in (A). Genes with MYC
in cyan.
(E) GSEA of multiple functionally defined MYC and E2F TF target gene sets was performed. Results are rep
intensity reflecting significance level.
(F) GSEA plots of functionally defined MYC and E2F target gene sets in vehicle- versus JQ1-treated cells at
(G) Protein abundance of MYC and E2F in the indicated DLBCL lines treated with vehicle or JQ1S or JQ1R
See also Figure S2 and Table S2.
Cancer Cell 24, 777–790,POU2AF1 has a large H3K27ac-
defined enhancer with strong BRD4 bind-
ing that is abolished by JQ1 treatment
(Figure 5A). Consistent with this observa-
tion, BET inhibition reduced RNA Pol II
elongation of POU2AF1, with a relative
increase in promoter-paused RNA Pol II
near the transcriptional start site (TSS;
Figure 5B). Notably, intronic enrichmentfor H3K4me3 and RNA Pol II was observed in POU2AF1, consis-
tent with an alternate promoter element, which was also affected
by JQ1 treatment. JQ1 treatment (500 nM) decreased OCA-B
transcript abundance and protein expression in Ly1 (Figure 5C),
as well as additional DLBCL cell lines (Figure S5A).
We next assessed the consequences of JQ1 treatment on
the OCA-B transcriptional program by performing GSEA with a
well-defined series of OCA-B target genes (Table S5, modified
from Teitell, 2003). OCA-B targets were downregulated in JQ1-
treated DLBCLs as illustrated in Ly1 (Figure 5D) and recapitu-
lated in the full DLBCL panel (Figures S5B and S5C). OCA-B
depletion with two independent small hairpin RNAs (shRNAs)
significantly decreased the proliferation of Ly1 (Figure 5E), and
enforced expression of OCA-B partially rescued the JQ1-medi-
ated antiproliferative effects (Figures S5D and S5E). Genetic
depletion of either BRD2 or BRD4 phenocopied the JQ1-medi-
ated reduction of OCA-B (Figures 5F, 5G, S5F, and S5G).ites in the regulatory region using the MSigDB.C3
binding sites are in green and E2F binding sites are
orted over time in a color-coded matrix with color
24 hr.
(500 nM; 24 hr).
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Figure 4. Asymmetric BRD4 Loading at Enhancer Elements of Actively Transcribed Genes
(A) Heatmap of ChIP-seq binding for H3K27ac (blue), BRD4 (red), and BCL6 (orange) rank ordered from high to low H3K27 occupancy centered on a ±5 kb
window around enhancers. Color density reflects enrichment; white indicates no enrichment.
(B) Metagenes created from normalized genome-wide average of reads for designated factors centered on a ±4 kb window around the enhancers.
(C) Venn diagram of BRD4 binding andH3K27ac occupancy. A total of 79.1%of H3K27ac regions contain BRD4, and 92.2%of all chromatin-bound BRD4 occurs
within H3K27ac regions.
(D) Pie chart of BRD4 binding to regions of the genome. BRD4 colocalization with H3K27ac without H3K4me3 defined as enhancer-bound (red); BRD4
colocalization with H3K4me3 reported as promoter-bound (gray); and remaining genomic regions in ‘‘other’’ (black).
(E) BRD4 loading/binding across enhancers of 18,330 genes. A total of 1.6% (285/18,330) of enhancers contain 32% of all enhancer-bound BRD4, with super-
loading defined as surpassing the inflection point. Top BRD4-superloaded enhancers are indicated.
(F) Mean transcript abundance of the genes associated with the 285 most and least BRD4-loaded enhancers (left and right panel, respectively) in five DLBCL cell
lines treated with vehicle or JQ1 (2–24 hr). Asterisks indicate a p < 0.0001 obtained using a two-sided Mann-Whitney U test.
See also Table S4 and Figure S4.
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Super-Enhancers in DLBCLTogether, these data underscore the importance of OCA-B to
DLBCL growth and illustrate the use of SEs to identify cancer
dependencies.
JQ1 Targets SEs of Additional Critical B Cell TFs and
Modulates the GC Program
Three of the master regulatory TFs with BRD4-loaded SEs
(BCL6, IRF8, and PAX5) promote and maintain the B cell gene
expression program and limit differentiation into antibody-
secreting plasma cells (Nutt et al., 2011). For these reasons,
we further assessed the functional consequences of BET inhibi-
tion on the critical B cell TFs with BRD4-loaded SEs.784 Cancer Cell 24, 777–790, December 9, 2013 ª2013 Elsevier Inc.Given the known oncogenic function of deregulated BCL6
in GC B cells (Basso and Dalla-Favera, 2012) and the sensitivity
of certain DLBCLs to BCL6 depletion (Polo et al., 2007), we first
evaluated the consequences of BET inhibition on BCL6 ex-
pression and function. The BCL6 locus includes a large previ-
ously defined upstream enhancer (Ramachandrareddy et al.,
2010) that is severely depleted of BRD4 upon JQ1 treatment
(Figure 6A). Consistent with depletion of BRD4 from the BCL6
enhancer, the promoter reveals a suggestion of increased RNA
Pol II pausing and reduced elongating RNA Pol II (Figure 6B).
JQ1 treatment markedly decreased BCL6 transcript abundance
and protein expression in Ly1 (Figures 6C and 6D) and additional
Figure 5. Identification of OCA-B as a DLBCL Dependency by SE Analysis
(A) ChIP-seq binding density for H3K27ac (blue) and BRD4 (red) at the enhancer of POU2AF1 following JQ1 (+) or vehicle (DMSO; ) treatment.
(B) ChIP-seq reads at the POU2AF1 promoter for RNA Pol II (black) and H3K4me3 (green) following JQ1 (+) or vehicle () treatment.
(C) OCA-B transcript and protein abundance in Ly1 cells treated with vehicle or 500 nM JQ1 or JQ1R (24 hr). Error bars represent SD.
(D) OCA-B target genes (leading edge, OCA-B GSEA) in Ly1 cells treated with vehicle or 500 nM JQ1 are visualized as heatmap.
(E) Knockdown efficacy of two independent OCA-B shRNAs was detected by western blot (top panel). Proliferation of OCA-B-depleted cells was measured by
alamar blue. The p values for control versus each OCA-B shRNA were delineated by two-sided Student’s t test; asterisks show p < 0.01. Error bars represent SD.
(F and G) Knockdown efficiency of two independent shRNAs against BRD4 (F) or BRD2 (G) and the associated changes in OCA-B expression were evaluated by
western blot.
See also Figure S5 and Table S5.
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Super-Enhancers in DLBCLDLBCL lines (Figure S6A). Interestingly, the observed broad
localization of BCL6 to its enhancer region was reduced by
JQ1 (Figures 6A and 6B), a finding we confirmed by ChIP-quan-
titative PCR (Figure S6B). This may reflect an influence of BET
inhibition on TF binding or a consequence of downregulation of
BCL6 by JQ1. Similarly, PAX5 and IRF8 also have BRD4-loaded
SEs that are severely depleted of BRD4 following JQ1 treatment
(Figure 6E). BET inhibition also decreased PAX5 and IRF8 tran-
script abundance and protein expression (Figures 6F and 6G).
SE Clustering Identifies Transcriptional Subtypes of
DLBCL
Using the robust H3K27acmark to identify and discriminate SEs,
we conducted ChIP-seq SE analysis on five additional humanCaDLBCL lines (DHL6, BCR/GCB; HBL1 and Ly3, BCR/ABC;
Toledo and Ly4, OxPhos/unclassified; Table S7) and a normal
lymphoid sample (tonsil; Table S7). Asymmetric enhancer
loading was detected in all of the DLBCL cell lines (Figures 7A–
7C) and the normal tonsil (Figure 7D), confirming the ubiquitous
nature of this epigenomic structural element.
In all of the DLBCL cell lines and normal tonsil, large SEs
were identified adjacent to genes encoding master TFs such
as PAX5, OCA-B, and IRF8 (Figures 7A–7F, tracks; Table S7)
that maintain the B cell program and limit plasma cell differen-
tiation. Given the critical role of these master regulatory TFs in
maintaining GC integrity and limiting GC exit (Nutt et al., 2011),
we functionally assessed the consequences of BET inhibition
on the GC program in all DLBCL cell lines. To that end, wencer Cell 24, 777–790, December 9, 2013 ª2013 Elsevier Inc. 785
Figure 6. BET Inhibition Modulates Tissue-Specifying TF Expression by Disrupting SEs
(A) ChIP-seq binding density for H3K27ac (blue), BRD4 (red), and BCL6 (orange) at the BCL6 enhancer following JQ1 (+) or vehicle (DMSO; ) treatment.
(B) ChIP-seq reads at the BCL6 promoter for RNA Pol II (black) and H3K4me3 (green) following JQ1 (+) or vehicle () treatment.
(C) BCL6 transcript abundance in Ly1 cells 12 and 24 hr following vehicle or JQ1 treatment (derived from GEP data). Error bars represent SD.
(D) BCL6 protein abundance following treatment with vehicle or JQ1 or JQ1R (500 nM; 24 hr).
(E) ChIP-seq density of BRD4 (red) at SEs of the two additional B cell TFs, PAX5 and IRF8, following treatment with JQ1 (+) or DMSO ().
(F and G) PAX5 and IRF8 transcript (F) and protein abundance (G) in Ly1 cells following JQ1 treatment. Error bars represent SD.
See also Table S6, Figure S6, and Supplemental Experimental Procedures.
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Super-Enhancers in DLBCLused publicly available gene expression profiles (GEP) of high-
ly purified human B cell subsets and defined a set of genes
that are significantly more abundant in GC centrocytes and
centroblasts than in post-GC plasma cells (UP_IN_GCB_
VS_PC). Using GSEA, we confirmed that this common GC
developmental program was downregulated in Ly1 and in all
five DLBCL cell lines following JQ1 treatment (Figures 7G,
7H, and S7B).
In a subset of the DLBCL cell lines, SEs were identified
adjacent to differentially expressed genes validated as discrimi-
nating DLBCL subtypes by the COO classification (Figure S7C;
Table S7). In the ABC DLBCL cell lines, but not the GCB lines,
the subtype-specific TF locus IRF4 had an adjacent SE (Fig-
ure 7A, GCB; Figure 7B, ABC; Figure 7F, tracks; Table S7). The
IRF4 SE was also detected in normal tonsil (Figure 7D), suggest-
ing that it represented a developmental epigenetic mark rather
than a tumor-specific feature. Additional genes associated with
the developmental ABC signature, including PIM1 and CCND2,
featured adjacent SEs in ABC, but not GCB, cell lines (Fig-786 Cancer Cell 24, 777–790, December 9, 2013 ª2013 Elsevier Inc.ure S7C; Table S7). Observing lineage-specifying genes flanked
by SEs, we explored whether SE analysis could independently
discriminate DLBCL subtypes. Indeed, unsupervised bidirec-
tional hierarchical clustering of DLBCL cell lines by SEs distin-
guished ABC from GCB cell lines (Figures 7I and S7C).
To evaluate the clinical significance of these findings, we
performed SE analysis on primary patient samples by genome-
wide ChIP-seq for H3K27ac on four primary DLBCLs that were
previously subtyped as either GCB or ABC (Monti et al., 2012).
All primary DLBCLs exhibited the same characteristic asymme-
try in H3K27ac enrichment, with readily identified regulatory
regions consistent with SEs (Figures 8A and 8B; Table S8).
Again, SEs were found adjacent to lineage-specifying TFs,
such as PAX5, and subtype-associated TFs, such as IRF4 (Fig-
ures 8A and 8B; tracks in Figures 8C and 8D; Table S8). Impor-
tantly, aggregate unsupervised hierarchical clustering of all SE
data principally segregated cell lines from primary samples
(malignant or nonmalignant), whereas isolated unsupervised
clustering of primary tissue segregated DLBCL samples in
Figure 7. Comparative SE Analysis of
DLBCL Cell Lines and Normal Lymphoid
Tissue
(A–D) Rank order of increasing integrated
H3K27ac fold enrichment at enhancer loci in
DLBCL cell lines GCB (A), ABC (B), unclassified
(C), and normal tonsil (D).
(E) H3K27ac ChIP-seq fold enrichment at the
PAX5 locus showing the SE region.
(F) H3K27ac ChIP-seq reads at IRF4 locus in the
two GCB and two ABC cell lines.
(G) GSEA plot of the ‘‘UP_IN GCB_VS_PC’’
signature in five DLBCL cell lines following JQ1
treatment.
(H) The leading edge genes of the GSEA in (G)
were visualized as heatmap.
(I) Similarity matrix from unsupervised hierarchical
clustering of each cell line by location of SEs.
See also Table S7 and Figure S7.
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Super-Enhancers in DLBCLagreement with transcriptional developmental distinctions (Fig-
ures 8E and S8; Table S8).
DISCUSSION
Here, we provide mechanistic evidence of BET bromodomains
as transcriptional coactivators at large enhancers and E2F1-
driven promoters and contribute data supporting the study of
BET inhibitors in all recognized subtypes of DLBCL. BET inhibi-
tion caused a profound G1 cell cycle arrest in a panel of DLBCL
cell lines representing all transcriptionally defined subtypes and
significantly delayed tumor growth in two independent DLBCL
xenograft models. Gene expression profiling of multiple JQ1-
treated DLBCL cell lines revealed downregulation of MYD88/
TLR and BCR signaling components, which are important for
certain subtypes of DLBCL (Chen et al., 2013; Ngo et al., 2011;
Nicodeme et al., 2010). More broadly relevant for all subtypesCancer Cell 24, 777–790,of DLBCLs, we identified highly signifi-
cant transcriptional downregulation of
MYC and E2F1 target genes and the
selective depletion of BRD4-loaded pro-
moters and enhancers.
BET inhibition decreased the abun-
dance of multiple functionally defined
E2F target genes, but did not measurably
alter E2F1 protein levels. Epigenomic
analyses confirmed the colocalization of
BRD4 and E2F1 at active promoters.
The selective decrease in BRD4 loading
of E2F1-driven genes following JQ1
treatment is consistent with studies sug-
gesting a role of BET proteins in E2F1-
mediated transcription (Peng et al.,
2007; Sinha et al., 2005). Genome-wide
assessment of effects of BRD4 on tran-
scriptional elongation at E2F1 target
genes was statistically significant but
subtle on an individual gene level (data
not shown), leaving open the possibilitythat BRD4-mediated effects on elongation are most apparent
on SE-associated genes. Given the recently identified structural
genetic signature of deregulated cell cycle and increased E2F
activity in poor-prognosis DLBCLs (Monti et al., 2012), BET inhi-
bition may represent a promising targeted treatment strategy.
Studies from our lab and others have highlighted the important
role of BRD4 as a coactivator of MYC-mediated transcription
(Delmore et al., 2011; Mertz et al., 2011; Ott et al., 2012). In
multiple myeloma cell lines with Ig/MYC translocations, BRD4
was postulated to function via long-range interactions with the
distal IgH enhancer (Delmore et al., 2011). However, emerging
data indicate that BET inhibitors suppress MYC transcription in
the context of translocated, amplified, or wild-type MYC alleles
and that BRD4 localizes to MYC promoter and enhancer
elements (Delmore et al., 2011; Love´n et al., 2013; Mertz et al.,
2011; Ott et al., 2012). In the current studies, we identify a
BRD4-loaded MYC enhancer and find that BET inhibitionDecember 9, 2013 ª2013 Elsevier Inc. 787
Figure 8. SE Analysis of Primary DLBCLs
(A and B) Rank order of increased H3K27ac fold
enrichment at enhancer loci in primary DLBCLs:
GCB#1 and #2 (A); ABC#1 and #2 (B).
(C) Gene tracks showing H3K27ac enrichment at
the PAX5 locus in all four primary DLBCLs.
(D) Tracks as in (C) comparing the H3K27 enrich-
ment at the IRF4 locus in primary GCB versus ABC
DLBCLs.
(E) Unsupervised hierarchical clustering of primary
DLBCLs using the genomic locations of all SEs in
Figure S7I.
See also Table S8 and Figure S8.
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Super-Enhancers in DLBCLdecreases MYC transcription and expression in DLBCL cell lines
with translocated, amplified, or wild-type MYC alleles. In this
extensive DLBCL cell line panel, the functional consequences
of BET inhibition—cell cycle arrest and decreased cellular prolif-
eration—were largely comparable. Although JQ1 treatment
broadly downregulated the transcriptional targets of MYC and
E2F, we sought additional bases for the effect of BET inhibition
across multiple DLBCL subtypes.
We observed that a small subset of genes had a disproportion-
ately high BRD4 load at their proximal enhancers. These unusual
regulatory elements were approximately 12-fold larger than
typical enhancer regions. Integrated epigenomic and transcrip-
tional studies established that such SE-marked genes were
particularly sensitive to BET inhibition. As SEs were found adja-
cent to genes encoding known lineage factors and DLBCL onco-
proteins, we surmised that SE analysis might identify previously
unrecognized tumor dependencies. The functional exploration of788 Cancer Cell 24, 777–790, December 9, 2013 ª2013 Elsevier Inc.OCA-B, encoded by SE-marked
POU2AF1, validates this factor as a
cancer dependency in DLBCL. Mecha-
nistic research has established OCA-B
as a coactivator protein that binds into
the OCT1-OCT2 transcriptional complex,
enhancing IgH promoter-enhancer com-
munication (Luo and Roeder, 1995; Ren
et al., 2011). Mice lacking OCA-B ex-
pression due to germline knockout of
POU2AF1 are developmentally normal,
even capable of early transcription from
immunoglobulin promoters; however,
they lack an apparent GC reaction to
antigen (Kim et al., 1996; Teitell, 2003).
Collectively, the earlier studies and the
current research support a putative ther-
apeutic window to targeting OCA-B,
potentially by protein-protein inhibition
via the POU domain. More generally,
these studies establish a rationale to
systematically explore SEs for unrecog-
nized tumor dependencies, and po-
tentially to use SEs as biomarkers for
targeted therapeutic development.
In this comparative epigenomic anal-
ysis of human DLBCL cell lines, primarytumor specimens, and normal lymphoid samples, we analyzed
patterns of H3K27ac enrichment to understand the relevance
of enhancer variation and function. These studies reveal SEs
as characteristic features of human lymphoid tissues, both
benign and malignant. Preservation of tissue-specific SEs is
observed, comparing nonmalignant nodal tissue to primary
DLBCL samples, as well as patient-derived human DLBCL cell
lines.
In summary, our data suggest that BET inhibition limits the
growth of DLBCLs by at least two complementary activities: a
specific effect on genes that define a given cell type by high
BRD4 loading at enhancers and a more general suppression of
transcription at E2F- and MYC-driven target genes. Thus, an
E2F/MYC pathway effect is combined with massive depletion
of proteins driven by BRD4-overloaded enhancers, preventing
cell cycle progression and leading to growth arrest. The majority
of DLBCLs have a structural basis for increased E2F1-mediated
Cancer Cell
Super-Enhancers in DLBCLcell cycle progression; however, these tumors may differ
in BRD4 super-loading of cell-fate-determining enhancers,
including MYC, depending on their molecular context. This
framework of BET inhibition explains its broad subclass- and
tumor-type-independent mechanism of action and reconciles
the apparent pleiotropic effects and cell type-specific outcomes.
Importantly, these data provide a compelling rationale for further
human clinical investigation.
EXPERIMENTAL PROCEDURES
High-Throughput Screening of BETBromodomain Inhibitors in BCell
Lymphoma Cell Line Panel
Using a semiautomated screen, we tested the indicated compounds in 34
human lymphoma lines in a 384-well format. Cell viability at 72 hr was evalu-
ated using ATPlite (Perkin Elmer). The means of absolute effective concentra-
tion of 50% impact (EC50) from two independent screens were visualized and
clustered using GENE-E (http://www.broadinstitute.org/cancer/software/
GENE-E/index.html).
Human Samples
Frozen biopsy specimens of newly diagnosed, previously untreated primary
DLBCLs with >80% tumor involvement and known transcriptional subtyping
(Monti et al., 2012) were obtained according to Institutional Review Board
(IRB)-approved protocols (Brigham and Women’s Hospital and Dana-Farber
Cancer Institute). A waiver to obtain informed consent was granted by the local
IRBs because only coded, deidentified, discarded tissue was used.
Animal Studies
All animal studies were performed according to Dana-Farber Cancer Institute
Institutional Animal Care and Use Committee-approved protocols, as previ-
ously described (Monti et al., 2012), and Supplemental Experimental
Procedures.
Analyses of Cellular Proliferation and Apoptosis,
Immunohistochemistry, Immunoblotting, Transcriptional Profiling,
GSEA and Lentiviral-Mediated shRNA, ChIP-Seq, and Analysis of
ChIP-Seq Data
A full description of these methods is listed in Supplemental Experimental
Procedures.
ACCESSION NUMBERS
The Gene Expression Omnibus accession numbers for the gene expression
and ChIP-seq data reported in this paper are GSE45630 and GSE46663,
respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and eight tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.11.003.
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